Market News AIOpen the app

CERENOME, INC.: Other Events (CNSY)

TrialRead the original at SEC EDGAR
Good for CNSY

Cerenome reported no progression by 3 or 6 months among 5 patients with enough follow-up, and no dose-limiting toxicities. One of 4 patients assessed had progression by 9 months, but the early safety and disease findings support repeat dosing.

CNSY · Cerenome, Inc.

AI read · Good for CNSY

The AI's read

That gives Cerenome early support for repeating its treatment. But the study is small and does not prove the treatment helps patients live longer. One patient later had disease progression, and one had severe nausea. More patients and dose testing are needed before the company can set a repeat-dose plan.

Get alerts for CNSY

Follow Cerenome, Inc. (CNSY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CNSY
Free on the App Store and Google Play, or on the web.